Carbiotix AB (CRBX) is an award-winning biotechnology company pioneering microbiome healthcare through a portfolio of prebiotic modulators and diagnostic testing services.
We are a company that is focused on continually innovating and improving our prebiotic products, how we deliver them to market, and how we verify their efficacy. In doing so, we are dedicated to delivering as much value as possible to our customers, partners, and other stakeholders. Carbiotix’s mission is to increase the consumption of prebiotics in people’s diets by:
Manufacturing the lowest cost and most effective prebiotics possible.
Selling these prebiotics through as many forms and channels as possible.
Providing the lowest cost consumer microbiome test possible.
Carbiotix was founded in 2014 based on four years of research at the Department of Biotechnology at Lund University and the Antidiabetic Food Centre (AFC) in Lund, Sweden.
In 2015, the company’s second-generation soluble fiber CarbiAXOS was selected as a top new ingredient by the Nutrition Capital Network in both Europe and the U.S.
In 2016, the company continued with the commercialisation of CarbiAXOS working in collaboration with industry leading partners across the supply chain.
In 2017, Carbiotix began development of its low-cost microbiome testing platform. The mission was to deliver an affordable low-cost microbiome test to consumers without cutting corners on quality.
In 2018, Carbiotix launched the LinkGut platform where customers could gain an accurate and informative overview of their gut health. During 2018, Carbiotix also commenced a 300-person gut health study to validate the LinkGut platform and a strategy to explore medical foods and therapeutics across multiple disease areas.
In 2019, the company began to leverage data from its low-cost microbiome testing platform to ramp up modulator development activities. These activities were in line with its long-term strategy to create microbiome modulators based on its proprietary soluble CarbiAXOS fiber, isolated strains, and novel delivery mechanisms.
In 2020, the Carbiotix laid out its strategy regarding modulators, with an initial focus on bringing to market CarbiAXOS. Carbiotix also communicated that it will focus on business to business services within the microbiome diagnostics area as a means to build relationships with modulator customers and advocates.
At the beginning of 2021, the company shifted its LinkGut service to solely an API service. This would allow the company to move away from data interpretation and focus on the logistics of offering a compelling microbiome test that is cost effective, reliable and flexible.
In June of 2022, Carbiotix opened it's first CarbiAXOS production site in Bjuv, Sweden.
Jonas Danielsson, Chairperson
Dr. Peter Falck, Ph.D
Dr. Gustav Wendel. M.D
Kristofer Cook, CEO
Henrik Ljung, CFO
Dr. Richard A. Rosenbloom, CMO
Martin Erlandsson, CIO
Stephen Bromley, CSO & CTO
Erik Deaner, COO
Professor Eva Nordberg Karlsson, Ph.D
Professor Patrick Adlercreutz, Ph.D
Dr. Jan Marsal, M.D, Ph.D